If after twelve weeks there is no improvement in fat mass or functional markers, it is reasonable to stop and reassess
2 Events related to a clinical picture of altered skin sensation such as sensitive skin, hyperesthesia, dysesthesia and paresthesia were reported by a higher proportion of participants, and at a higher rate, in the Wegovy HD arm (22%), compared to treatment with Wegovy 2.4 mg (6%) and placebo (0.3%)
Types of GLP-1 agonists GLP-1 agonists are either short- or long-acting medications, depending on how long their effects last
If you need a wide selection of GLP-1 options, Willows menu is thin
This chart is also a nice illustration of how IP strategy shapes the timeline
But the specific synergy remains theoretical